title: Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.
abstract: Abiraterone plus prednisone prolongs overall survival relative to prednisone alone in patients with metastatic castration-resistant prostate cancer who have disease progression after treatment with docetaxel. The survival gain observed in this pivotal trial is accomplished with few adverse events and conclusively demonstrates that patients with castration levels of serum testosterone remain sensitive to additional hormonal manipulation.
authors.affiliation: Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA. osartor@tulane.edu
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000737:Androstenols / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000726:Androgen Antagonists; D000737:Androstenols; D013254:Steroid 17-alpha-Hydroxylase